Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.
Susceptibility (18 antimicrobial agents including high-dose tobramycin) and checkerboard synergy (23 combinations) studies were performed for 2,621 strains of Burkholderia cepacia complex isolated from 1,257 cystic fibrosis patients. Minocycline, meropenem, and ceftazidime were the most active, inhibiting 38%, 26%, and 23% of strains, respectively. Synergy was rarely noted (range, 1% to 15% of strains per antibiotic combination).
Zhou
Juyan
J
Division of Infectious Diseases, Department of Pediatrics, Columbia University, College of Physicians & Surgeons, 650 West 168th Street, PH 4 West Room 470, New York, NY 10032, USA.
Chen
Yunhua
Y
Tabibi
Setareh
S
Alba
Luis
L
Garber
Elizabeth
E
Saiman
Lisa
L
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D019121:Burkholderia Infections / Q000382:microbiology*; D042602:Burkholderia cepacia complex / Q000187:drug effects*; D003550:Cystic Fibrosis / Q000150:complications* / Q000382:microbiology*; D024901:Drug Resistance, Multiple, Bacterial; D004357:Drug Synergism; D006801:Humans; D008826:Microbial Sensitivity Tests
D000900:Anti-Bacterial Agents